Evidence map›Paper›PMID 33344817›Full record

ArticleACS omega2020

Preclinical Evaluation of a Novel

Peng Liu, Tingting Wang, Rongshui Yang, Wentao Dong, Qiang Wang, Zhide Guo, Chao Ma, Weixing Wang, Huaibo Li, Xinhui Su

Open access · goldAbstract read
In one paragraph

Article in ACS omega, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. LongitudinalFrontiers in chemistry · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Peng LiuDepartment of Nuclear Medicine, Zhongshan Hospital Xiamen University, Xiamen 361004, China.
Tingting WangDepartment of Nuclear Medicine, Zhongshan Hospital Xiamen University, Xiamen 361004, China.
Rongshui YangDepartment of Nuclear Medicine, Zhongshan Hospital Xiamen University, Xiamen 361004, China.
Wentao DongDepartment of Nuclear Medicine, Zhongshan Hospital Xiamen University, Xiamen 361004, China.
Qiang WangDepartment of Nuclear Medicine, Zhongshan Hospital Xiamen University, Xiamen 361004, China.
Zhide GuoCenter for Molecular Imaging and Translational Medicine, Xiamen University, Xiamen 361102, China.
Chao MaDepartment of Nuclear Medicine, Zhongshan Hospital Xiamen University, Xiamen 361004, China.
Weixing WangDepartment of Nuclear Medicine, Zhongshan Hospital Xiamen University, Xiamen 361004, China.
Huaibo LiDepartment of Health Medicine, Zhongshan Hospital Xiamen University, Xiamen 361004, China.
Xinhui SuDepartment of Nuclear Medicine, Zhongshan Hospital Xiamen University, Xiamen 361004, China.
Zhongshan Hospital of Xiamen University · CNXiamen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Early diagnosis and therapy are crucial to control disease progression optimally and achieve a good prognosis in rheumatoid arthritis (RA). Previous study showed that a technetium-99m (

Identifiers

PMID33344817
PMCPMC7745438
OpenAlexW3108598694

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.